| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.11 | 0.009 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.071 | 0.01 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.01 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.01 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.01 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | 0.078 | 0.01 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.19 | 0.01 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.27 | 0.02 |